Get the Stockscreener App
12.72
4.69%
0.57
After Hours:
12.72
Novocure Ltd stock is traded at $12.72, with a volume of 2.34M.
It is up +4.69% in the last 24 hours and up +8.44% over the past month.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
See More
Previous Close:
$12.15
Open:
$12.39
24h Volume:
2.34M
Relative Volume:
1.48
Market Cap:
$1.42B
Revenue:
$577.74M
Net Income/Loss:
$-149.78M
P/E Ratio:
-9.0857
EPS:
-1.4
Net Cash Flow:
$-78.21M
1W Performance:
+0.95%
1M Performance:
+8.44%
6M Performance:
-34.74%
1Y Performance:
-31.50%
1-Day Range:
$12.07
$12.77
1-Week Range:
$11.98
$12.84
52-Week Range:
$10.87
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
12.72 | 1.36B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
131.33 | 232.75B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
99.87 | 152.19B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
377.11 | 146.55B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
93.43 | 120.61B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
76.05 | 45.54B | 5.69B | 1.41B | 577.90M | 6.95 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-04-23 | Initiated | SVB Securities | Outperform |
| Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
| Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
| May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
| May-16-22 | Initiated | H.C. Wainwright | Buy |
| Feb-08-22 | Initiated | Loop Capital | Buy |
| Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
| Jan-25-21 | Reiterated | Piper Sandler | Overweight |
| Sep-23-20 | Initiated | Northland Capital | Outperform |
| Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-17-20 | Downgrade | Truist | Buy → Hold |
| Jun-01-20 | Resumed | Oppenheimer | Perform |
| May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
| Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-16-18 | Initiated | Evercore ISI | Outperform |
| Apr-18-18 | Reiterated | Mizuho | Buy |
| Feb-23-18 | Reiterated | Mizuho | Buy |
| May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jul-29-16 | Reiterated | Wedbush | Outperform |
| Jan-19-16 | Initiated | Barclays | Underweight |
| Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
NovoCure (NVCR) Gains Japan Approval For Optune Lua® In NSCLC Treatment Combo - simplywall.st
Union Pacific, Corteva, Novocure - TradingView
Japan approves Novocure’s Optune Lua for advanced lung cancer treatment - Investing.com India
Novocure (NVCR) Gains Approval in Japan for Cancer Treatment - GuruFocus
8-Month Survival Boost: Novocure's Optune Lua Device Approved in Japan for Advanced Lung Cancer Treatment - Stock Titan
NovoCure Limited $NVCR Shares Sold by Teza Capital Management LLC - MarketBeat
NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer - MSN
NovoCure Limited (NASDAQ:NVCR) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
How Investors May Respond To NovoCure (NVCR) FDA Approval of Optune Lua for Lung Cancer - simplywall.st
NovoCure (NASDAQ:NVCR) Shares Gap Up Following Insider Buying Activity - MarketBeat
Insider Buying: NovoCure (NASDAQ:NVCR) CEO Purchases 81,550 Shares of Stock - MarketBeat
Cinctive Capital Management LP Lowers Stake in NovoCure Limited $NVCR - MarketBeat
Cubist Systematic Strategies LLC Sells 83,600 Shares of NovoCure Limited $NVCR - MarketBeat
Graham Capital Management L.P. Grows Stock Holdings in NovoCure Limited $NVCR - MarketBeat
Novocure at Morgan Stanley Healthcare Conference: Expanding Cancer Treatment Horizons - Investing.com
NovoCure (NVCR): Evaluating Valuation After FDA Approval of Optune Lua and Shifts in Investor Positioning - simplywall.st
Hsbc Holdings PLC Sells 37,369 Shares of NovoCure Limited $NVCR - MarketBeat
70,795 Shares in NovoCure Limited $NVCR Purchased by American Century Companies Inc. - MarketBeat
Is NovoCure Limited a turnaround storyMarket Activity Report & Community Trade Idea Sharing Platform - Lancaster City Council
Novocure at H.C. Wainwright: Strategic Growth in Cancer Treatment - Investing.com
What earnings revisions data tells us about NovoCure Limited2025 Trading Recap & Reliable Breakout Stock Forecasts - Newser
Will NovoCure Limited see short term momentumJuly 2025 Highlights & Real-Time Market Sentiment Alerts - Newser
What to expect from NovoCure Limited in the next 30 daysWeekly Trend Report & Safe Capital Growth Plans - Newser
Hedge Fund and Insider Trading News: Ken Griffin, Steve Cohen, Anthony Scaramucci, Bill Ackman, Marshall Wace, Point72 Asset Management, Third Point, Brevan Howard, Audioeye Inc (AEYE), NovoCure Ltd (NVCR), and More - Insider Monkey
Top chart patterns to watch in NovoCure LimitedMarket Sentiment Report & AI Forecast for Swing Trade Picks - Newser
NovoCure Limited Stock (NVCR) Opinions on FDA Approval of Optune Lua Device - Quiver Quantitative
Novocure CEO Cordova buys shares worth $996k By Investing.com - Investing.com South Africa
Novocure CEO Cordova buys shares worth $996k - Investing.com India
How to monitor NovoCure Limited with trend dashboards2025 Institutional Moves & Weekly High Potential Alerts - Newser
Novocure announces coverage for Tumor Treating Fields therapy in Spain - MSN
Will NovoCure Limited continue its uptrend2025 Fundamental Recap & Daily Stock Momentum Reports - Newser
NovoCure Limited $NVCR Shares Purchased by Palo Alto Investors LP - MarketBeat
Can NovoCure Limited continue delivering strong returnsJuly 2025 Rallies & Reliable Entry Point Trade Alerts - خودرو بانک
Is NovoCure Limited stock undervalued right nowPortfolio Performance Report & Capital Efficiency Focused Ideas - خودرو بانک
Loss Report: Can NovoCure Limited deliver consistent dividendsShare Buyback & Expert Verified Stock Movement Alerts - خودرو بانک
What machine learning models say about NovoCure Limited2025 Market Outlook & Real-Time Buy Zone Alerts - Newser
How to build a dashboard for NovoCure Limited stockRate Hike & Daily Stock Trend Reports - Newser
Northern Trust Corp Has $22.02 Million Stock Holdings in NovoCure Limited $NVCR - MarketBeat
Novocure at Wells Fargo Conference: Expanding Cancer Treatment Horizons - Investing.com
Novocure at Wells Fargo Conference: Expanding Cancer Treatment Horizons By Investing.com - Investing.com UK
Is NovoCure Limited exposed to currency risks2025 Market WrapUp & Weekly Top Gainers Trade List - خودرو بانک
American Century Companies Inc. Invests $1.26 Million in NovoCure Limited $NVCR - Defense World
Strategies to average down on NovoCure LimitedJuly 2025 Outlook & Technical Pattern Based Buy Signals - Newser
Does NovoCure Limited show high probability of reboundEarnings Growth Summary & Consistent Return Strategy Ideas - Newser
Can NovoCure Limited recover in the next quarterTrend Reversal & Verified Technical Signals - Newser
What the charts say about NovoCure Limited today2025 AllTime Highs & Low Drawdown Investment Ideas - Newser
Understanding NovoCure Limited’s price movementWeekly Stock Report & AI Enhanced Trade Execution Alerts - Newser
Is NovoCure Limited a top pick in the sectorJuly 2025 Summary & Daily Chart Pattern Signals - خودرو بانک
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novocure Ltd Stock (NVCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Brackmann Christoph | Chief Financial Officer |
Jul 29 '25 |
Buy |
11.59 |
20,000 |
231,800 |
141,150 |
| Stafford Kristin | Director |
Jun 03 '25 |
Sale |
17.28 |
999 |
17,259 |
3,054 |
| LEUNG GABRIEL | Director |
Jun 03 '25 |
Sale |
17.31 |
999 |
17,297 |
81,229 |
| Madden Martin J. | Director |
Jun 03 '25 |
Sale |
17.19 |
999 |
17,176 |
18,674 |
| Scannell Timothy J | Director |
Jun 03 '25 |
Sale |
17.32 |
999 |
17,299 |
6,018 |
| HILLEMAN JERYL L | Director |
Jun 03 '25 |
Sale |
17.26 |
999 |
17,247 |
5,591 |
| Ocean Allyson J | Director |
Jun 03 '25 |
Sale |
17.29 |
999 |
17,269 |
3,054 |
| VERNON W ANTHONY | Director |
Jun 03 '25 |
Sale |
17.35 |
999 |
17,329 |
167,887 |
| Hung David | Director |
Jun 03 '25 |
Sale |
17.30 |
999 |
17,280 |
12,195 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Jun 02 '25 |
Sale |
17.50 |
30,196 |
528,413 |
168,452 |
0.44%
1.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):